Mereo BioPharma Group PLC

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on rare diseases. Founded in 2015, it acquires high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies for strategic reasons, and develops them with a capital-efficient model. Its pipeline is focused on two lead rare disease programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). The company is listed on NASDAQ under the ticker MREO and is headquartered in London, United Kingdom.

Mereo BioPharma Group plc was founded in 2015, empowered by the recognition that there are many high-potential novel therapies that are not being progressed in pharmaceutical or biotechnology companies. In 2015, the company acquired three quality clinical stage product candidates from Novartis, and in 2017 it acquired one from AstraZeneca. In 2019, Mereo merged with OncoMed, which provided its NASDAQ listing, strengthened its balance sheet and broadened its shareholder base. In late 2020, Mereo signed a license and collaboration agreement with Ultragenyx for its clinical development program in osteogenesis imperfecta, retaining commercial rights in Europe.

Clinical-stage biopharmaceutical company focused on rare diseases, operating a capital-efficient model and forming strategic partnerships.

• 2020-11-23

  Mereo BioPharma announces clinical development SVP appointment[6]Mereo BioPharma宣布临床开发高级副总裁任命biospace.com

  Reported: 2020-11-23

  Mereo BioPharma announced Suba Krishnan, M.D.'s appointment as Senior Vice President of Clinical Development, effective December 7, 2020.

1. 1Home | Mereo BioPharmamereobiopharma.com
2. 2About Us: Our Vision and how we work | Mereo BioPharmamereobiopharma.com
3. 3Investors - Value Creation in Rare Disease | Mereo BioPharmamereobiopharma.com
4. 4Careers in Rare Disease Therapeutics | Mereo BioPharmamereobiopharma.com
5. 5Mereo BioPharma Group PLC (United Kingdom)wikidata.org
6. 6Mereo BioPharma宣布临床开发高级副总裁任命biospace.com